Copyright
©The Author(s) 2020.
World J Gastroenterol. Sep 7, 2020; 26(33): 4960-4971
Published online Sep 7, 2020. doi: 10.3748/wjg.v26.i33.4960
Published online Sep 7, 2020. doi: 10.3748/wjg.v26.i33.4960
Figure 1 Flow diagram of patients enrolled in the present study.
Bone mineral density was assessed at the lumbar spine (L2-L4), femoral neck, and total hip in 405 chronic liver disease patients. One hundred thirty-eight patients were diagnosed with osteoporosis (34.1%); among these, 78 patients met the exclusion criteria and 60 patients were finally included in the present study. CLD: Chronic liver disease.
- Citation: Saeki C, Saito M, Oikawa T, Nakano M, Torisu Y, Saruta M, Tsubota A. Effects of denosumab treatment in chronic liver disease patients with osteoporosis. World J Gastroenterol 2020; 26(33): 4960-4971
- URL: https://www.wjgnet.com/1007-9327/full/v26/i33/4960.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i33.4960